Taiwan · Delayed Price · Currency is TWD SCI Pharmtech Statistics
Total Valuation
SCI Pharmtech has a market cap or net worth of TWD 6.43 billion. The enterprise value is 7.41 billion.
| Market Cap | 6.43B |
| Enterprise Value | 7.41B |
Important Dates
The next estimated earnings date is Wednesday, September 9, 2026.
| Earnings Date | Sep 9, 2026 |
| Ex-Dividend Date | Jul 1, 2026 |
Share Statistics
SCI Pharmtech has 119.51 million shares outstanding. The number of shares has decreased by -0.17% in one year.
| Current Share Class | 119.51M |
| Shares Outstanding | 119.51M |
| Shares Change (YoY) | -0.17% |
| Shares Change (QoQ) | -0.17% |
| Owned by Insiders (%) | 4.95% |
| Owned by Institutions (%) | 0.60% |
| Float | 69.49M |
Valuation Ratios
The trailing PE ratio is 107.51.
| PE Ratio | 107.51 |
| Forward PE | n/a |
| PS Ratio | 5.10 |
| PB Ratio | 1.21 |
| P/TBV Ratio | 1.22 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 28.72 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 123.20 |
| EV / Sales | 5.88 |
| EV / EBITDA | 24.56 |
| EV / EBIT | 162.60 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.25, with a Debt / Equity ratio of 0.20.
| Current Ratio | 1.25 |
| Quick Ratio | 0.33 |
| Debt / Equity | 0.20 |
| Debt / EBITDA | 2.95 |
| Debt / FCF | -6.08 |
| Interest Coverage | 13.83 |
Financial Efficiency
Return on equity (ROE) is 1.12% and return on invested capital (ROIC) is 1.29%.
| Return on Equity (ROE) | 1.12% |
| Return on Assets (ROA) | 0.93% |
| Return on Invested Capital (ROIC) | 1.29% |
| Return on Capital Employed (ROCE) | 1.71% |
| Weighted Average Cost of Capital (WACC) | 3.79% |
| Revenue Per Employee | 5.27M |
| Profits Per Employee | 251,536 |
| Employee Count | 245 |
| Asset Turnover | 0.18 |
| Inventory Turnover | 1.42 |
Taxes
In the past 12 months, SCI Pharmtech has paid 15.96 million in taxes.
| Income Tax | 15.96M |
| Effective Tax Rate | 20.98% |
Stock Price Statistics
The stock price has decreased by -9.75% in the last 52 weeks. The beta is 0.01, so SCI Pharmtech's price volatility has been lower than the market average.
| Beta (5Y) | 0.01 |
| 52-Week Price Change | -9.75% |
| 50-Day Moving Average | 50.01 |
| 200-Day Moving Average | 48.96 |
| Relative Strength Index (RSI) | 59.19 |
| Average Volume (20 Days) | 207,397 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, SCI Pharmtech had revenue of TWD 1.26 billion and earned 60.12 million in profits. Earnings per share was 0.50.
| Revenue | 1.26B |
| Gross Profit | 305.16M |
| Operating Income | 104.02M |
| Pretax Income | 76.08M |
| Net Income | 60.12M |
| EBITDA | 353.28M |
| EBIT | 104.02M |
| Earnings Per Share (EPS) | 0.50 |
Balance Sheet
The company has 84.07 million in cash and 1.06 billion in debt, with a net cash position of -976.75 million or -8.17 per share.
| Cash & Cash Equivalents | 84.07M |
| Total Debt | 1.06B |
| Net Cash | -976.75M |
| Net Cash Per Share | -8.17 |
| Equity (Book Value) | 5.31B |
| Book Value Per Share | 44.43 |
| Working Capital | 214.49M |
Cash Flow
In the last 12 months, operating cash flow was 223.89 million and capital expenditures -398.32 million, giving a free cash flow of -174.44 million.
| Operating Cash Flow | 223.89M |
| Capital Expenditures | -398.32M |
| Depreciation & Amortization | 249.26M |
| Net Borrowing | 167.81M |
| Free Cash Flow | -174.44M |
| FCF Per Share | -1.46 |
Margins
Gross margin is 24.21%, with operating and profit margins of 8.25% and 4.77%.
| Gross Margin | 24.21% |
| Operating Margin | 8.25% |
| Pretax Margin | 6.04% |
| Profit Margin | 4.77% |
| EBITDA Margin | 28.03% |
| EBIT Margin | 8.25% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.75, which amounts to a dividend yield of 1.34%.
| Dividend Per Share | 0.75 |
| Dividend Yield | 1.34% |
| Dividend Growth (YoY) | -50.00% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 298.19% |
| Buyback Yield | 0.17% |
| Shareholder Yield | 1.51% |
| Earnings Yield | 0.94% |
| FCF Yield | -2.71% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 27, 2023. It was a forward split with a ratio of 1.125.
| Last Split Date | Jul 27, 2023 |
| Split Type | Forward |
| Split Ratio | 1.125 |
Scores
SCI Pharmtech has an Altman Z-Score of 2.99 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.99 |
| Piotroski F-Score | 5 |